The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award
The Belgian Association of Clinical Research Professionals has presented its European outstanding leadership award to Jan Geissler and Dr. Georges Niset.
The group presented Geissler, director of the European Patients' Academy on Therapeutic Innovation, EUPATI) and patient advocate, with the ACRP.be award “in recognition of his exceptional performance and leadership within EUPATI, in particular by addressing training issues and by improving the availability of both patient-centric information for the public as well as educated patient experts that have the capacity and capability to contribute to R&D.”
The leadership award is presented annually to individuals who have demonstrated exceptional performance, achievement and sustained service toward the goals of ACRP and the contributions to the advancement of clinical research in general.
"I feel deeply honored to accept this award on behalf of my fellow patient advocates as well as the EUPATI team," Geissler said. "The fact that this award of research professionals is being provided to patient advocates, as well as to EUPATI being a partnership of patient organizations, academia and industry, is a reflection of the paradigm shift: patients are increasingly seen as true partners in medicines R&D. The ACRP and EUPATI share an important mission: building the capacity and capability of both clinical research professionals as well as expert patients."
The other recipient, Dr. Georges Niset, is Secretary of the Ethics Committee at Erasme-ULB in Belgium.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.